4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-012662
Chief Scientific Officer sold 800 shares at an average $36.27 ($29,018)
- Chief Scientific Officer acquired 800 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-02-18 | Exercise or conversion : show line 1 in the form | +800 | $7.26 | $5,808 | 12,800 | D |
| 2021-02-18 | Sale : show line 2 in the form | −600 | $35.81 | $21,484 | 12,200 | D |
| 2021-02-18 | Sale : show line 3 in the form | −200 | $37.67 | $7,534 | 12,000 | D |
| Open-market sales · 800 sh · avg $36.27 · $29,018 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2021-02-18 | Exercise or conversion : show line 4 in the form Employee Stock Option (right to buy) | −800 | $7.26 | 2030-02-26 | 800 | 75,866 | D |
Loading xslF345X03/doc4.xml…